After he spoke in June 2012 the stock never stopped going up week after week because of his confidence and how well the phase IIb was trending. Now this company is 15 months into a registrational phase III with DMC and two interim look-ins. The world knows bavituximab doubled survival in 2nd line NSCLC. We could today be at the 30% improvement in mos over control group for the first 120 patients???? Will the FDA do the right thing and halt the trial this summer when Avid is at full steam ready for commercialization???
PPHM is the most undervalued stock on the NASDAQ.
We may go down here and there, but imo month after month from here on in PPHM goes up to true value 1-2B, until we here trial halted. Then value will double or triple that day.
News 
Market Data 
Discover 
